Education
About Us
Working with TipRanks
Follow Us
Co-Diagnostics (CODX)
:CODX
CODX Stock Chart & Stats
$0.32
-$0.07(-8.42%)
At close: 4:00 PM EST
$0.32
-$0.07(-8.42%)
Day’s Range― - ―
52-Week Range$0.23 - $1.29
Previous CloseN/A
Volume146.43K
Average Volume (3M)10.09M
Market Cap
$15.61M
Enterprise Value-$2.38M
Total Cash (Recent Filing)$13.36M
Total Debt (Recent Filing)$1.70M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Nov 06, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding48,142,582
10 Day Avg. Volume1,334,715
30 Day Avg. Volume10,088,102
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.15
Enterprise Value/Revenue-2.37
Enterprise Value/Gross Profit-5.99
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$0.50Price Target Upside56.25% Upside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsManagement expects to initiate clinical evaluations for all tests in the pipeline before the end of 2025.
Financial PerformanceNet loss was $7.7M, or ($0.23) per share, less than the estimated loss of $8.3M.
Bears Say
Capital RequirementsThe company needs to raise additional capital in the near term to fund operations.
Commercial SuccessFailure to achieve commercial success due to market size, penetration rate, and/or competition is a risk.
Regulatory RisksThere is a risk of failure in clinical evaluations and failure to secure regulatory clearance for the instrument and/or tests in the U.S.
Co-Diagnostics News
CODX FAQ
What was Co-Diagnostics’s price range in the past 12 months?
Co-Diagnostics lowest stock price was $0.23 and its highest was $1.29 in the past 12 months.
What is Co-Diagnostics’s market cap?
Co-Diagnostics’s market cap is $15.61M.
When is Co-Diagnostics’s upcoming earnings report date?
Co-Diagnostics’s upcoming earnings report date is Nov 06, 2025 which is in 18 days.
How were Co-Diagnostics’s earnings last quarter?
Co-Diagnostics released its earnings results on Aug 14, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.02.
Is Co-Diagnostics overvalued?
According to Wall Street analysts Co-Diagnostics’s price is currently Undervalued.
Does Co-Diagnostics pay dividends?
Co-Diagnostics does not currently pay dividends.
What is Co-Diagnostics’s EPS estimate?
Co-Diagnostics’s EPS estimate is -0.18.
How many shares outstanding does Co-Diagnostics have?
Co-Diagnostics has 48,142,582 shares outstanding.
What happened to Co-Diagnostics’s price movement after its last earnings report?
Co-Diagnostics reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went up 11.538%.
Which hedge fund is a major shareholder of Co-Diagnostics?
Currently, no hedge funds are holding shares in CODX
Co-Diagnostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.50 (56.25% Upside)
$0.50 (56.25% Upside)
Hedge Fund Trend
Decreased
By 36.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 11.9%
Last 30 Days ▲ 11.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.08%
12-Months-Change
Fundamentals
Return on Equity
-63.40%
Trailing 12-Months
Asset Growth
-42.42%
Trailing 12-Months
Company Description
Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
CODX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted significant advancements in Co-Diagnostics' Co-DX PCR platform development, supported by major grants and upcoming clinical evaluations. However, these positives were overshadowed by a sharp revenue decline and increased losses, indicating financial challenges.View all CODX earnings summariesCODX Stock 12 Month Forecast
Average Price Target
$0.50
▲(56.25% Upside)
Technical Analysis
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―
Ownership Overview
4.21% Insiders
4.17% Mutual Funds
0.06% Other Institutional Investors
88.32% Public Companies and
Individual Investors